Lilly says the 12 mg dose cut weight 21% versus 9% on Ozempic over 80 weeks, though 8% quit over side effects compared with 3% on Novo's drug.
Recap by typeshit. Full story at Yahoo Finance.
PHL17 shares findings that people on Ozempic and similar drugs are cutting alcohol spending at bars, restaurants and home.
Omer Raheem says he presented his team's work on GLP-1 therapies past weight loss at the ISSM Journals Webinar 2026.
The rundown covers CagriSema, retatrutide, MariTide, VK2735 and Roche's enicepatide, which the company says cut weight by 15.5% on average in a mid-stage trial.
Zhavoronkov links recorded ARDD 2026 sessions, among them Lilly's Kevin Duffin speaking on tirzepatide and aging clocks.
Up to 52% of patients on retatrutide went from severe apnea to mild or none over 80 weeks, against 13% on placebo, researchers report. The drug isn't approved yet.
STAT notes RFK Jr. and the MAHA movement have embraced peptides, though evidence for many of these wellness compounds is thin. A July FDA panel backed all six.
Loading…